The investment round was led by GV, the venture capital arm of Google’s parent company Alphabet, with additional funding from ARCH Venture Partners, F-Prime Capital, and Biomatics Capital.
Sekar Kathiresan, MD, former director of the center for genomic medicine at Massachusetts General Hospital, was named Verve’s CEO, effective in July. The company has already secured partnerships with CRISPR-focused biotech company Beam Therapeutics and Alphabet’s life sciences research subsidiary Verily, as well as MIT and Harvard University’s Broad Institute for biomedical and genomic research.
Verve’s mission is to use genetic analysis and genomic editing to discover and develop a one-time therapy that will protect adults at risk of coronary artery disease, the leading cause of death in the U.S.
More articles about health IT:
AI detects anxiety, depression in children’s speech patterns
Starbucks to adopt Microsoft’s blockchain service
IBM completes blockchain pilot with Syniverse
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
